Compare iShares MSCI Taiwan ETF (EWT) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs HCA Health Inc — how do they compare? iShares MSCI Taiwan ETF trades at $106.32, while HCA Health Inc trades at $416.09 (market cap $89.08B). The key difference: HCA Health Inc pays a 0.76% dividend while iShares MSCI Taiwan ETF pays none, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, HCA Health Inc nearer its low. Which is the better fit depends on your goals.
| EWT | HCA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $111.53 | $545.13 |
52-Week Low | $58.05 | $361.32 |
Market Cap | — | $89.08B |
Enterprise Value | — | $139.62B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $106.34, up 4.07% with strong bullish momentum. Technical indicators show moving averages strongly bullish while oscillators are neutral. The ETF benefits from Taiwan's AI-driven semiconductor exposure, with TSMC representing 22.5% weighting. Recent news highlights Taiwan's strong 2026 performance driven by AI chip demand, though some rotation from Asian AI winners has occurred.
Outlook remains positive given Taiwan's critical semiconductor role and AI infrastructure demand. Key risks include geopolitical tensions with China, foreign capital outflows, and semiconductor cycle volatility. The ETF's heavy tech concentration provides growth potential but increases sector-specific risk exposure.
HCA Healthcare trades at $413.27, down 0.18% on the day, with strong technical momentum showing a bullish moving average signal. The company reported solid Q2 2026 earnings with EPS of $7.59 beating estimates of $7.56, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $75.60 billion, while maintaining healthy profit margins of 8.77%. Recent management appointments and ongoing legal investigations create mixed sentiment around the stock.
HCA presents a compelling value opportunity with attractive valuation multiples (P/E 13.8, EV/EBITDA 8.8) and strong analyst support (63% buy ratings, $449.93 price target). However, investors face risks from multiple ongoing legal investigations, high debt levels (debt-to-asset ratio 80.9% in 2025), and margin pressure from rising operational costs. The stock offers 8.9% upside to consensus target but requires monitoring of legal developments and expense management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
